NCT03242590View on ClinicalTrials.gov

Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021).

PHASE3CompletedINTERVENTIONAL
Enrollment

95

Participants

Timeline

Start Date

December 31, 2016

Primary Completion Date

March 31, 2017

Study Completion Date

July 31, 2017

Conditions
Hypogonadism, Male
Interventions
DRUG

LPCN 1021

Oral testosterone undecanoate

Sponsors

Lead Sponsor

Lipocine Inc.
All Listed Sponsors
lead

Lipocine Inc.

INDUSTRY

NCT03242590 - Dosing Validation Study of Oral Testosterone Undecanoate (TU, LPCN 1021). | Biotech Hunter | Biotech Hunter